Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.

MLA

Kindler HL, et al. “Gemcitabine plus Sorafenib in Patients with Advanced Pancreatic Cancer: A Phase II Trial of the University of Chicago Phase II Consortium.” Investigational New Drugs, vol. 30, no. 1, Feb. 2012, pp. 382–86. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=104627952&authtype=sso&custid=ns315887.

APA

Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, & Vokes EE. (2012). Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Investigational New Drugs, 30(1), 382–386.

Chicago

Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, and Vokes EE. 2012. “Gemcitabine plus Sorafenib in Patients with Advanced Pancreatic Cancer: A Phase II Trial of the University of Chicago Phase II Consortium.” Investigational New Drugs 30 (1): 382–86. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=104627952&authtype=sso&custid=ns315887.